Daniel E. Meyers
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
-
- Immunotherapy and Immune Responses
Papers in
- Oncology 19
- Cancer Immunotherapy and Biomarkers 15
- CAR-T cell therapy research 5
- Lung Cancer Research Studies 3
-
- Lung Cancer Treatments and Mutations 5
- Co-authors
- Don G. Morris (13 shared papers)Igor Stukalin (15 shared papers)Shantanu Otto Banerji (4 shared papers)Aliyah Pabani (10 shared papers)Tina Cheng (8 shared papers)Kristina Jenei (5 shared papers)Daniel Yick Chin Heng (6 shared papers)Michelle Liane Dean (3 shared papers)
- Journals
- JAMA Network Open (4 papers)Journal of Cancer Policy (2 papers)Frontiers in Oncology (2 papers)JAMA Oncology (2 papers)Cancer Medicine (2 papers)
- Partner nations
- CanadaUnited StatesDenmark
In The Last Decade
Daniel E. Meyers
36 papers receiving 712 citations
Daniel E. Meyers's Hit Papers
Peers
Comparison fields: 5 of 70
- Oncology 378
- Immunology 78
- Pulmonary and Respiratory Medicine 110
- Pharmacology 27
- Hepatology 21
Countries citing papers authored by Daniel E. Meyers
This map shows the geographic impact of Daniel E. Meyers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Meyers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Meyers more than expected).
Fields of papers citing papers by Daniel E. Meyers
This network shows the impact of papers produced by Daniel E. Meyers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Meyers. The network helps show where Daniel E. Meyers may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel E. Meyers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors Hit paper breakdown → | 2024 | 90 |
| 2 | 2019 | 61 | |
| 3 | 2018 | 60 | |
| 4 | 2022 | 53 | |
| 5 | 2018 | 48 | |
| 6 | 2021 | 38 | |
| 7 | 2021 | 34 | |
| 8 | 2018 | 29 | |
| 9 | 2021 | 25 | |
| 10 | 2013 | 22 | |
| 11 | 2017 | 22 | |
| 12 | 2021 | 21 | |
| 13 | 2017 | 20 | |
| 14 | 2022 | 20 | |
| 15 | 2020 | 20 | |
| 16 | 2020 | 18 | |
| 17 | 2020 | 18 | |
| 18 | 2021 | 18 | |
| 19 | 2023 | 17 | |
| 20 | 2023 | 11 |
About Daniel E. Meyers
Daniel E. Meyers is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Hepatology, Economics and Econometrics and Pharmacology, having authored 37 papers that have together received 720 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (15 papers), CAR-T cell therapy research (5 papers), Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (3 papers), Virus-based gene therapy research (3 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers), Cancer Research and Treatments (2 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). The work is most often cited by research in Oncology (378 citations), Immunology (78 citations), Pulmonary and Respiratory Medicine (110 citations), Pharmacology (27 citations) and Hepatology (21 citations). Daniel E. Meyers has collaborated with scholars based in Canada, United States and Denmark. Frequent co-authors include Don G. Morris, Igor Stukalin, Shantanu Otto Banerji, Aliyah Pabani, Tina Cheng, Kristina Jenei, Daniel Yick Chin Heng, Michelle Liane Dean, Bishal Gyawali and Vishal Navani. Their work appears in journals such as JAMA Network Open, Journal of Cancer Policy, Frontiers in Oncology, JAMA Oncology and Cancer Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.